U.S. markets open in 3 hours 43 minutes

  • S&P Futures

    4,131.25
    +7.75 (+0.19%)
     

  • Dow Futures

    33,952.00
    +18.00 (+0.05%)
     

  • Nasdaq Futures

    12,559.75
    +44.25 (+0.35%)
     

  • Russell 2000 Futures

    1,967.40
    +2.30 (+0.12%)
     

  • Crude Oil

    75.82
    +1.71 (+2.31%)
     

  • Gold

    1,885.40
    +5.90 (+0.31%)
     

  • Silver

    22.33
    +0.09 (+0.40%)
     

  • EUR/USD

    1.0724
    -0.0007 (-0.06%)
     

  • 10-Yr Bond

    3.6340
    0.0000 (0.00%)
     

  • Vix

    19.30
    +0.97 (+5.29%)
     

  • GBP/USD

    1.2000
    -0.0024 (-0.20%)
     

  • USD/JPY

    131.9000
    -0.7070 (-0.53%)
     

  • BTC-USD

    23,021.98
    +196.05 (+0.86%)
     

  • CMC Crypto 200

    529.09
    +3.96 (+0.75%)
     

  • FTSE 100

    7,881.50
    +44.79 (+0.57%)
     

  • Nikkei 225

    27,685.47
    -8.18 (-0.03%)
     

X4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency Candidate

2
Vandana Singh
·1 min read

  • X4 Pharmaceuticals Inc (NASDAQ: XFOR) announced topline results from the pivotal Phase 3 (4WHIM) trial of its lead investigational therapy, mavorixafor, a novel CXCR4 antagonist, in people with WHIM syndrome.

  •  Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) is a rare congenital immune deficiency in which individuals are more susceptible to potentially life-threatening bacterial infections.

  • 4WHIM met its primary endpoint, with mavorixafor achieving clinical and statistical superiority over placebo when measuring TATANC, or the length of time that participants' absolute neutrophil counts (ANC) remained above a clinically meaningful threshold of 500 cells per microliter (severe neutropenia), over 24-hour periods at 4 time points throughout the 52-week trial.

  • Related: X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia.

  • Mean TATANC was 15.04 hours in the treatment group versus 2.75 hours in the placebo group.

  • 4WHIM also met a key secondary endpoint, with mavorixafor achieving clinical and statistical superiority over placebo when measuring TATALC, or the length of time that participants' absolute lymphocyte counts (ALC) remained above a clinically meaningful threshold of 1,000 cells per microliter (lymphopenia), over 24-hour periods at 4 time points throughout the 52-week trial. Mean TATALC was 15.80 hours in the treatment group versus 4.55 hours in the placebo group.

  • Mavorixafor was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events.

  • Price Action: XFOR shares are 17.30% lower at $1.53 during premarket trading on Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • Jim Cramer Makes a Surprising Admission About Tesla

    The outspoken CNBC host and contributor makes his case when asked which automaker stock he'd rather own.

  • Two Intel rivals positioned to dominate the chip industry, report says

    Intel is facing a "changing of the guard" in the chip industry as two competitors steal a page for its playbook, according to an analysis published by Bloomberg last week. After Intel Corp. (Nasdaq: INTC) reported earnings reflecting an "astonishingly bad" performance, two rivals, Taiwan Semiconductor Manufacturing Co. (NYSE: TSM) and Samsung have proved themselves as better positioned to weather a current demand downturn, according to Bloomberg. TSMC in particular "has caught and passed Intel quicker than even the most optimistic analysts had predicted," the according to the report.

  • ‘Big Short’ hedge funder says he thinks we’re headed for a ‘run-of-the-mill’ recession—but the bigger ‘paradigm shift’ is really on his mind

    Steve Eisman says some market paradigms get deeply embedded in people’s minds. “They can’t even imagine, at times, that there could be anything else.”

  • Bed Bath & Beyond announces plan to raise $1 billion, stock falls 24%

    Bed Bath & Beyond's (BBBY) stock sank 24% after the embattled retailer announced it will raise as much as $1.025 billion through an equity offering.

  • India's Adani crisis spills over into street protests as losses top $110 billion

    The crisis engulfing the Adani Group intensified on Monday as hundreds of members of India's opposition parties took to the streets to press for a probe into allegations by a U.S. short-seller against the conglomerate which triggered its market rout. Shares in billionaire Gautam Adani's companies have been in free-fall since a Jan. 24 critical report by Hindenberg Research, with group cumulative market losses now topping $110 billion, sparking fears of wider financial contagion. Opposition parties, who last week called for a parliamentary panel to investigate the saga and disrupted proceedings, have questioned Indian Prime Minister Narendra Modi's closeness with Adani.

  • Why Plug Power Stock Fell 5% Today

    Shares of hydrogen fuel cell company Plug Power (NASDAQ: PLUG) were down about 5.5% as of 1:30 p.m. ET on Monday, presumably responding to a report from Euronews that suggested the prospects for building a hydrogen economy may no longer be as bright as once thought. Citing data from non-governmental organization Global Witness, Euronews noted today that converting Europe's economy alone to run on hydrogen gas would cost 240 billion euros -- and double the cost of electricity for consumers. Over the past few years, predictions for the growth rate of the hydrogen economy have been ... optimistic, shall we say.

  • Laid-off Silicon Valley workers are panic-selling their start-up shares as valuations plunge — here are 3 top tech stocks for 2023 that actually make money

    It's a tech-astrophe out there. But you have options.

  • Tesla Stock Rallies 58% YTD, Top Analyst Says Don't Sell Yet

    Tesla has gained 91% since Jan. 6 bear-market lows, but this Tesla bull just hiked his stock price target.

  • Baidu Surges as Hope Mounts over Chinese Answer to ChatGPT

    (Bloomberg) -- Baidu Inc. surged after affirming it’s on track to publicly roll out its ChatGPT-like service in March, stoking anticipation around what is potentially China’s most prominent entry in the race to create lifelike AI bots.Most Read from BloombergQuake Toll Hits 4,000 in Turkey, Syria as Overseas Aid FlowsTurkey’s South Hit by a Second High-Magnitude EarthquakeDell to Cut About 6,650 Jobs, Battered by Plunging PC SalesUS Moves to Recover Chinese Balloon While Weighing RetaliationChin

  • ATVI Q4 earnings 'impressive' despite MSFT acquisition 'distraction': CFRA VP

    John Freeman, CFRA Vice President, Equity Research, discusses Take-Two Interactive and Activision Blizzard earnings.  You can see the full interview here. Key video highlights 00:00 On earnings surprise 00:11 On Call of Duty 00:33 On video game business

  • You'll Never Believe the 'Dumbest' Stock Warren Buffett Ever Bought

    Business magnate Warren Buffett has long been hailed as one of the greatest value investors in modern America. Through decades of mergers and acquisitions, great investments and adhering to austere investing principles, Buffett earned this title as well as the title World's Richest Person in 2008. Buffett invested in the early stages of The Coca-Cola Co., American Express Co. and several other modern behemoths, mostly before they were the titans you know today. But even Buffett has made some poo

  • EV Startup Canoo Makes a Big Announcement

    Canoo , a young electric vehicle manufacturer, just made a big announcement to help pursue its efforts to supply delivery vehicles to WalMart and others. The company, which began testing vehicles late last year with WalMart, raised additional capital on Monday by selling new shares to institutional investors. The new shares were sold to investors at a discount in a direct offering and will net Canoo $52.5 million.

  • Pinterest (PINS) Tops Q4 Earnings Estimates

    Pinterest (PINS) delivered earnings and revenue surprises of 3.57% and 0.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Why Lumen Technologies Stock Tumbled by 4% on Monday

    It's rarely comforting when an institutional investor cuts its stake in a company. In a regulatory document filed that morning, financial services company State Street disclosed that it currently holds just under 53.9 million shares of Lumen's common stock, giving it a stake of slightly over 5.2% in the telecom. State Street has not yet publicly commented on its shift, nor has Lumen formally addressed it.

  • Artificial Intelligence Stocks To Watch: Big Tech Expands AI Products, Services

    When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge.

  • Is Social Security income taxable by the IRS? Here's what you might owe on your benefits

    How is social security taxed in 2023? Here are the rules used to calculate how much you might owe on your benefits.

  • 2 Cathie Wood Growth Stocks Up 30% or More to Buy and Hold for 10 Years

    These favorites of the Ark Invest founder and her team are shaping up to be great long-term stories.

  • Why C3.ai Stock Popped Again Today

    Shares of C3.ai (NYSE: AI), the artificial intelligence-based software-as-a-service company, were moving higher again as the stakes continued to build in artificial intelligence and investors continue to look to C3.ai as one of the few pure plays available in AI. Coming on the heels of news that ChatGPT's has reached 100 million users and it would charge $20 a month for a "plus" tier, Google said today that it was launching its own conversational search tool, named Bard. Bard isn't live, but Google said it will be made available in the coming weeks and is now being opened up to "trusted testers."

  • Ask an Advisor: I'm Over Age 72. How Do I Avoid the RMD Tax Bite?

    I'm over age 72. What can I do about avoiding the required minimum distribution (RMD) tax bite? I have a steady stream of other income. -Bernie Tax-deferred accounts, such as 401(k)s and traditional individual retirement accounts (IRAs), are potentially great … Continue reading → The post Ask an Advisor: I'm Over Age 72. How Do I Avoid the RMD Tax Bite? appeared first on SmartAsset Blog.

  • Google Has a ChatGPT Rival; That's Not What Has People Laughing

    In the case of Alphabet , the answer could leave one open to the slings and arrows of outrageous social media snark. Google announced a new conversational AI technology on Feb. 6 that the search engine giant said it will open up to public testing "in the coming weeks." Bard is seen as a rival to ChatGPT, a conversational robot with which humans can converse in natural language.